PIN injection plus Sintilimab for advanced colorectal cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—an injection directly into liver tumors (PIN) plus an immunotherapy (Sintilimab) given through a vein—for people with advanced colorectal cancer that has spread to the liver and has not gotten better after at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have colorectal cancer that has spread to the liver and has not responded to at least two prior treatments.
- Your tumor must be a type called pMMR or MSS (a test will confirm this).
- You must have at least one liver tumor that is large enough (≥1 cm) and safely reachable with a needle for injection.
- You must be willing to have a new biopsy of your tumor during the study.
- You must be in generally good health (adequate organ function) and not have serious infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
This trial tests a new combination of two drugs, pirfenidone and sintilimab, added to standard chemotherapy before surgery for colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis). The goal is to see if this combination helps shrink the cancer more effectively.
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
This trial is testing a combination of two drugs – sintilimab (an immunotherapy that helps your immune system fight cancer) and gossypol acetate (a targeted therapy) – for people with advanced colorectal cancer that has not responded to at least two prior treatments and whose tumors have a specific genetic profile (pMMR/MSS).
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.